Geftinat 250 mg : Geftinib Natco Uses, Side Effect, Price, Cost India.
Geftinat 250mg
Drug profile of Geftinat
Geftinat 250mg tablets are cipla manufactured product which is endorsed by FDA with anti-neoplastic activity.Geftinat 250mg containing active constituent known as Gefitinib is an inhibitor of epidermal growth factor receptor.
Geftinat 250mg is only powerful in tumor cells which get mutated & uncontrolled EGFR.
Chemically Geftinat 250mg Tablets is categorized as anilinoquinazoline with anti-tumor activity.
Geftinat 250mg is pharmacologically classified as;
 |
| Geftinat 250mg |
PRODUCT DETAILS
Brand name: Geftinat
Active substance: Gefitinib
Strength: 250mg
Mfg: Cipla
Pack: 30 tablets in a container
Classified as: EFGR inhibitor, kinase inhibitor or Anti-neoplastic agent
Prescribing information of Geftinat
Geftinat 250mg tablets are therapeutically indicated in the conditions like;
Non small cell lung cancer only suggested after the failure of therapies with platinum based compounds & docetaxel chemotherapies.
In adults, Geftinat is used for the treatment of long lasting advanced stage of non small cell lung cancer.
Geftinat is a first line therapy; used in NSCLC patients with EFGR exon 19 deletions or exon 21 mutations.
The potency of Gefitinib has not been evaluated completely in advanced NSCLC with EGFR exon 19 deletions or exon 21 mutations.
Geftinat 250mg containing Gefitinib expels anti-tumor activity.
Gefitinib works by prohibiting tyrosine kinase phosphorylation occurs intracellularly which is related to cell surface receptors.
Gefitinib acts on cell surface of tumors by interfering with signal transduction by epidermal growth factor receptor.
This signal transfer is responsible for tumor cell division, blockade of apoptosis & elevating the production of angiogenic factors which is inducing metastasis.
Finally the inhibition of signal transduction stops all these functions of tumor cells leads to lyses.
Food does not interfere with absorption, no chances occur in bioavailability
Gefitinib is largely bound to human plasma protein with the range of 90%.
86% through feces;
Less than 4% through urine
When to take the Geftinat 250mg tablets
Geftinat 250mg tablets should be taken with or without food.
If patient fail to administer Geftinat 250mg tablet orally, tablet should be dissolved with 4 to 8 ounces of water and drink it or administer through naso gastric tube immediately after dispersion.
Dose alteration;
In some serious cases, the dose of Geftinat 250mg should be altered for reducing the adverse effects related to Geftinat 250mg.
Conditions like;
Geftinat 250mg tablets should be stopped under the conditions like;
Dose variation occurs in drug interaction
While concurrent use of Geftinat with strong CYP3A4 inducers, the dose of Geftinat 250mg is increased to 500mg daily taken as a single dose and continue to take 250mg for 7 days after CYP3A4 inducers discontinuation.
In hepatic impaired patients, the plasma concentration of Gefitinib gets elevated.
In renal impaired patients, dosage adjustment should not be suggested in CrCl >20ml/min.
Elder patients have poor liver & kidney mechanism, no dosage adjustment should be provided.
Skin reactions like rashes, Pruritus, dry skin, acne
Loss of weight
Anorexia
Conjunctivitis
Corneal erosion
Geftinat 250mg combined with strong CYP3A4 inducers like rifampicin, anti-convulsants causes elevating the Gefitinib metabolism and depletes the Gefitinib concentration.
To avoid this problem, the dose of Geftinat 250mg should be increased to 500mg then continue the therapy with 250mg as a single dose after the discontinuation of CYP3A4 inducers drugs.
Geftinat 250mg tablets co administered with strong CYP3A4 inhibitors causes diminishing the Gefitinib metabolism leads to increase the plasma concentration.
Geftinat 250mg should not be co administered with gastric regulator drugs, causes reduction in plasma concentration of Gefitinib.
Administration of Geftinat 250mg tablets should be taken with the dosing interval of 6 hours after or before the H2 receptor antagonist.
Administration of Geftinat 250mg tablets should be taken with the dosing interval of 12 hours after or before the proton pump inhibitors.
Possible contraindications of Geftinat 250mg.
Geftinat 250mg is contraindicated to pregnancy & lactating women
Some hypersensitivity reactions may produce due to patients contraindicated to the component of Geftinat 250mg tablets.
Gefitinib did not produce any genetic defects. Carcinogenesis, mutagenesis or fertility impairment may occur. Avoid getting pregnancy during the therapy with Geftinat 250mg.
Patient with Lapp lactose deficiency, galactose intolerance, or glucose-galactose malabsorption should not take this medication due to presence of lactose in Gefitinib
Geftinat 250mg with NSAIDS causes GI perforations
Severe ocular disorders like keratitis, conjunctivitis may occur
Geftinat 250mg tablets should not be prescribed for pregnancy condition
Breast feeding should not be allowed, contraindicated
Protect the container from moisture, heat & light.
In this condition discontinue the Geftinat 250mg therapy.
Active substance: Gefitinib
Strength: 250mg
Mfg: Cipla
Pack: 30 tablets in a container
Classified as: EFGR inhibitor, kinase inhibitor or Anti-neoplastic agent
Prescribing information of Geftinat
Geftinat 250mg tablets are therapeutically indicated in the conditions like;
Non small cell lung cancer only suggested after the failure of therapies with platinum based compounds & docetaxel chemotherapies.
In adults, Geftinat is used for the treatment of long lasting advanced stage of non small cell lung cancer.
Geftinat is a first line therapy; used in NSCLC patients with EFGR exon 19 deletions or exon 21 mutations.
The potency of Gefitinib has not been evaluated completely in advanced NSCLC with EGFR exon 19 deletions or exon 21 mutations.
Mechanism of Geftinat
Geftinat 250mg containing Gefitinib expels anti-tumor activity.
Gefitinib works by prohibiting tyrosine kinase phosphorylation occurs intracellularly which is related to cell surface receptors.
Gefitinib acts on cell surface of tumors by interfering with signal transduction by epidermal growth factor receptor.
This signal transfer is responsible for tumor cell division, blockade of apoptosis & elevating the production of angiogenic factors which is inducing metastasis.
Finally the inhibition of signal transduction stops all these functions of tumor cells leads to lyses.
Absorption
The absorption of Geftinat 250mg occurs gradually and reaches peak plasma levels within 3 to 7 hours.Food does not interfere with absorption, no chances occur in bioavailability
Distribution
Gefitinib is widely distributed in the body; the apparent volume of distribution is 1400LGefitinib is largely bound to human plasma protein with the range of 90%.
Excretion
Elimination of Gefitinib 250mg occurs through;86% through feces;
Less than 4% through urine
When to take the Geftinat 250mg tablets
Geftinat 250mg tablets should be taken with or without food.
If patient fail to administer Geftinat 250mg tablet orally, tablet should be dissolved with 4 to 8 ounces of water and drink it or administer through naso gastric tube immediately after dispersion.
Dosage regimens of Geftinat
The usual prescribed dose of Geftinat 250mg tablets are 250mg tablet should be administered orally as a single dose until unpleasant toxicities occurs.Dose alteration;
In some serious cases, the dose of Geftinat 250mg should be altered for reducing the adverse effects related to Geftinat 250mg.
Conditions like;
Geftinat 250mg tablets should be stopped under the conditions like;
Dose variation occurs in drug interaction
While concurrent use of Geftinat with strong CYP3A4 inducers, the dose of Geftinat 250mg is increased to 500mg daily taken as a single dose and continue to take 250mg for 7 days after CYP3A4 inducers discontinuation.
In pediatric:
Geftinat 250mg tablets potency and effectiveness has not been identified in pediatric patients who are less than 18 years of age.In hepatic impaired patients, the plasma concentration of Gefitinib gets elevated.
In renal impaired patients, dosage adjustment should not be suggested in CrCl >20ml/min.
Elder patients have poor liver & kidney mechanism, no dosage adjustment should be provided.
Geftinat caused side effects
DiarrheaSkin reactions like rashes, Pruritus, dry skin, acne
Loss of weight
Anorexia
Conjunctivitis
Corneal erosion
Drug - drug interaction of Geftinat
The major drug interaction occurs in Gefitinib therapy;Geftinat 250mg combined with strong CYP3A4 inducers like rifampicin, anti-convulsants causes elevating the Gefitinib metabolism and depletes the Gefitinib concentration.
To avoid this problem, the dose of Geftinat 250mg should be increased to 500mg then continue the therapy with 250mg as a single dose after the discontinuation of CYP3A4 inducers drugs.
Geftinat 250mg tablets co administered with strong CYP3A4 inhibitors causes diminishing the Gefitinib metabolism leads to increase the plasma concentration.
Geftinat 250mg should not be co administered with gastric regulator drugs, causes reduction in plasma concentration of Gefitinib.
Administration of Geftinat 250mg tablets should be taken with the dosing interval of 6 hours after or before the H2 receptor antagonist.
Administration of Geftinat 250mg tablets should be taken with the dosing interval of 12 hours after or before the proton pump inhibitors.
Possible contraindications of Geftinat 250mg.
Geftinat 250mg is contraindicated to pregnancy & lactating women
Some hypersensitivity reactions may produce due to patients contraindicated to the component of Geftinat 250mg tablets.
Safety measures of Geftinat
Pulmonary toxicity like interstitial lung disease, cough, and pulmonary edema may occur during the therapy, to avoid these risk cases postpone or discontinue the treatment with Geftinat 250mg tablets.Gefitinib did not produce any genetic defects. Carcinogenesis, mutagenesis or fertility impairment may occur. Avoid getting pregnancy during the therapy with Geftinat 250mg.
Patient with Lapp lactose deficiency, galactose intolerance, or glucose-galactose malabsorption should not take this medication due to presence of lactose in Gefitinib
Geftinat 250mg with NSAIDS causes GI perforations
Severe ocular disorders like keratitis, conjunctivitis may occur
Pregnancy and lactation
Pregnancy category of Gefitinib DGeftinat 250mg tablets should not be prescribed for pregnancy condition
Breast feeding should not be allowed, contraindicated
Storage and handling
Geftinat 250mg tablet container should be kept in cool & dry place with controlled temperature of 20oC to 25oC.Protect the container from moisture, heat & light.
Over dosage
Avoid missed dose.In this condition discontinue the Geftinat 250mg therapy.
CONTACT DETAILS
Website : https://pillsbag.com/products/geftinatAddress : Old.No.131,New.No.50,Pedariyar kovil street
Seven wells,Chennai-600001.Tamilnadu,India
Email : millionhealthpharmaceuticals@gmail.com
Comments
Post a Comment